Health
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE® (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous (SC) do
About this update from Johnson & Johnson
[{"type":"text","content":"Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2","length":92,"tagName":"p"},{"type":"text","content":"Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6","length":138,"tagName":"p"},{"type":"text","content":"HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE® (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous (SC) dosing schedule.1,2","length":585,"tagName":"p"},{"type":"image","alt":"Johnson & Johnson (PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"Johnson & Johnson (PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":38,"url":"https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l1P3ZFYFL52xeQr0zq6rKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721","width":400,"height":38}},"href":"https://mma.prnewswire.com/media/2343818/Johnson_and_Johnson_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This milestone builds upon the recent FDA approval of RYBREVANT FASPRO™, which transformed administration time from hours to minutes and offers a fivefold reduction in administration-related reactions (ARRs), when compared to intravenous (IV) delivery. With this newly approved monthly dosing schedule, patients are able to transition to monthly dosing as early as Week 5. Together, these advances build on an unmatched survival benefit while supporting continued treatment optimization, further simplifying care delivery and offering greater convenience.1","length":561,"tagName":"p"},{"type":"text","content":""A monthly dosing schedule offers patients convenience without sacrific...